Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology (symbol: CYAD) is a clinical-stage biopharmaceutical company founded in 2007. The company is renowned for its expertise in cell-based therapies, particularly in taking them from the initial research phase to Phase III clinical trials. Celyad boasts robust manufacturing and logistical infrastructure designed to support the development of complex cell-based products.
Celyad's business model is rooted in strategic partnerships with esteemed research institutions such as Dartmouth College. These collaborations are instrumental in advancing their innovative programs from bench research to commercial applications.
One of the company's major focus areas is immuno-oncology, where it is pioneering the development of natural killer receptor T-cells (NKR-T cells) aimed at treating cancer. This unique therapeutic approach has shown promise in targeting and potentially destroying a wide variety of tumor types, positioning Celyad at the forefront of cancer treatment innovation.
Listed on Euronext Brussels, Euronext Paris, and NASDAQ under the ticker symbol CYAD, Celyad continues to gain recognition for its groundbreaking work in the biotech industry. The financial condition of the company is robust, with ongoing projects that underscore its commitment to transforming cancer care. Recent achievements and current projects reflect a steadfast dedication to clinical excellence and innovation.
Celyad Oncology (CYAD) reported its 2021 results, showing a net loss of €26.5 million or €1.70 per share, a significant increase from €17.2 million or €1.23 per share in 2020. The company had cash and equivalents of €30 million as of Dec 31, 2021, expected to fund operations until mid-2023. Clinical updates included encouraging results from the Phase 1 IMMUNICY-1 trial of CYAD-211 for relapsed/refractory multiple myeloma, while the CYAD-101 Phase 1b trial is on clinical hold. The firm anticipates upcoming data releases and IND submissions in 2022.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced it will report its full year 2021 financial and operational results on March 24. Following the results, management will host a conference call on March 25 at 1 p.m. CET to discuss the outcomes and provide updates on recent progress and milestones. Celyad specializes in the development of CAR T cell therapies for cancer treatment, focusing on both allogeneic and autologous therapies to address various malignancies.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that the U.S. FDA placed a clinical hold on its CYAD-101-002 (KEYNOTE-B79) Phase 1b trial on March 1, 2022, due to insufficient risk assessment data. This decision follows the company's voluntary pause of the trial on February 28, 2022, after reports of two fatalities. Celyad specializes in CAR T cell therapies for cancer treatment, focusing on both allogeneic and autologous candidates.
Celyad Oncology SA (CYAD) has announced a voluntary pause of the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to reports of two fatalities with similar pulmonary issues. This trial investigates the CYAD-101 therapy, designed for patients with refractory metastatic colorectal cancer. The company prioritizes patient safety and is investigating these serious incidents while keeping regulatory bodies informed. Previous trials with CYAD-101 showed no dose-limiting toxicities. Celyad anticipates no impact on its other candidates, including CYAD-211 for multiple myeloma.
Celyad Oncology announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference from February 14 to 18, 2022, with a presentation scheduled for February 18 at 8 a.m. ET by CEO Filippo Petti. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including both allogeneic and autologous treatments for hematological malignancies and solid tumors. Celyad has received funding from the Walloon Region of Belgium to support its CAR T programs.
Celyad Oncology (CYAD) announces promising advancements in its allogeneic CAR T therapies, highlighting 2021's achievements and 2022 goals. The company aims to deliver key data from the KEYNOTE-B79 and IMMUNICY-1 clinical trials for CYAD-101 and CYAD-211 as they progress. The proprietary shRNA technology has been validated, offering a competitive edge, while a recent $32.5 million investment from Fortress Investment Group strengthens its financial position. Celyad ended 2021 with a treasury of €30 million ($34 million), ensuring funding into mid-2023.
Celyad Oncology SA announced a capital increase on
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced an issuance of 6,500,000 new shares on December 8, 2021, to Fortress Investment Group. This capital increase raises the company's share capital to 78,584,224.33 EUR with a total of 22,593,956 shares now outstanding. The decision aligns with Belgian law on the disclosure of major participations. Post-issuance, there are 20,225,931 shares with single voting rights and 2,368,025 shares with double voting rights. Additionally, the total diluted shares amount to 24,591,146.
Celyad Oncology SA (CYAD), a clinical-stage biotechnology firm, has announced its participation in the H.C. Wainwright BioConnect 2022 Conference, taking place from January 10 to January 13, 2022. CEO Filippo Petti will present on-demand starting January 10 at 7 a.m. ET. Celyad is focused on developing CAR T cell therapies for various cancers, and is progressing with both allogeneic and autologous therapy candidates. The company has received funding from the Walloon Region in Belgium to support its development programs.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced a transparency notification on December 17, 2021, revealing that Tolefi SA and related individuals have crossed the 20% voting rights threshold, now holding 18.65% as of December 8, 2021. This notification signals a downward passive crossing of the threshold by persons acting in concert, emphasizing significant shareholder concentration which could influence company governance. The total number of voting rights is reported at 24,961,981.
FAQ
What is the market cap of CYAD (CYAD)?
What does Celyad Oncology specialize in?
When was Celyad Oncology founded?
On which stock exchanges is Celyad listed?
What is the company's ticker symbol?
Who are Celyad's key research partners?
What are natural killer receptor T-cells (NKR-T cells)?
What is Celyad's business model?
What are some recent achievements of Celyad Oncology?
What is the status of Celyad's financial condition?
How can I stay updated on Celyad's latest news?
